| Status: AWMSG assessment in progress | |
For routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype. |
|
Medicine details |
|
| Medicine name | emicizumab (Hemlibra®) |
| Formulation | subcutaneous injection |
| Reference number | 4742 |
| Indication | As above |
| Company | Roche Products Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | Limited |
| Status | AWMSG assessment in progress |
| Scrutiny Panel meeting date | 03/11/2025 |
| LOWMAG meeting date | TBC |
| AWMSG meeting date | TBC |